Sequana Medical NV (EBR:SEQUA)

Belgium · Delayed Price · Currency is EUR

0.6110

0.00 (0.00%)

At close: Oct 9, 2026

Market Cap	43.56M -13.7%
Revenue (ttm)	n/a -85.2%
Net Income	-51.85M
EPS	-1.11
Shares Out	71.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	0.6110
Day's Range	n/a
52-Week Range	0.4600 - 0.8770
Beta	-0.30
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 14, 2026

About Sequana Medical NV

Sequana Medical NV develops and commercializes treatments for patients with diuretic-resistant fluid overload in liver disease, cancer, and heart failure in Belgium, Germany, France, and internationally. The company offers alfapump system, an implantable pump system for the treatment of refractory liver ascites and malignant ascites; and Direct Sodium Removal (DSR) for the treatment of fluid overload spread across the body. Sequana Medical NV was founded in 2006 and is headquartered in Gent, Belgium. [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2006

Employees 48

Stock Exchange Euronext Brussels

Ticker Symbol SEQUA

Full Company Profile

Financial Performance

In 2024, Sequana Medical NV's revenue was 105,500, a decrease of -85.19% compared to the previous year's 712,173. Losses were -44.65 million, 37.1% more than in 2023.

Financial Statements